Skip to main
IMCR

Immunocore Holdings (IMCR) Stock Forecast & Price Target

Immunocore Holdings (IMCR) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 44%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

Immunocore Holdings PLC's KIMMTRAK has achieved a strong market presence, beating quarterly sales estimates in 12 out of 14 quarters since its launch, indicating consistent commercial success in treating unresectable or metastatic uveal melanoma. The company is expanding its pipeline with multiple candidates targeting various therapeutic areas, including the promising TEBE-AM which could enhance the product's commercial opportunities beyond its current indications, potentially leading to peak annual revenues in the range of $500 million. Additionally, the validation of its PRAME franchise and continuous progress in clinical trials further emphasize the company's robust growth trajectory and strong foundation for future revenue expansion.

Bears say

Immunocore Holdings PLC's stock outlook is negatively impacted by underwhelming data from recent clinical trials, particularly in cutaneous melanoma and ovarian cancer, revealing low objective response rates (11% and 6% respectively). The company faces increased competition from emerging therapies, notably IDYA's darovasertib, which poses a threat to Kimmtrak's market share in the HLA-A2+ mUM space, likely affecting its peak market potential. Additionally, Immunocore's pipeline presents high uncertainty due to regulatory and commercial risks, compounded by visibility issues regarding the success of clinical trials for oncology and autoimmune disease programs.

Immunocore Holdings (IMCR) has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 44% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunocore Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunocore Holdings (IMCR) Forecast

Analysts have given Immunocore Holdings (IMCR) a Buy based on their latest research and market trends.

According to 9 analysts, Immunocore Holdings (IMCR) has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $60.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $60.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunocore Holdings (IMCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.